Age-Related Macular Degeneration (AMD) Global Market Report 2022: Upcoming Treatments to Redefine the Sector – ResearchAndMarkets.com

DUBLIN-(BUSINESS WIRE)–The “Age-Related Macular Degeneration (AMD) Market, Global Forecast 2023-2028, Industry Trends, Growth, Inflation Impact, Opportunity Company Analysis” report has been added to ResearchAndMarkets.com supply.

The age-related macular degeneration market will reach USD 14.06 billion in 2028, according to the publisher. Age-related macular degeneration (AMD) is an eye disease that can get worse over time. It is the leading cause of severe, permanent vision loss in people over 60. It occurs when the small central part of the retina, called the macula, wears away. Aging population and high morbidity are boosting the market growth.

For example, UNDESA publishes data on the population over the age of 65, which is about 727 million in 2020. By the end of 2050, the geriatric population will be approximately 2 billion. Dry macular and wet macular degeneration are the two main types of macular wear and tear leading to the disorder. Both are potentially fatal and require treatment with drugs. The potential market for the treatment of age-related macular degeneration is growing in response to increasing demand from the elderly. According to our research findings, the age-related macular degeneration industry will expand at a CAGR of 8.5% from 2022 to 2028.

Increased reimbursement incentives for age-related macular degeneration (AMD) drugs are helping to improve the industry. Additionally, increasing incidence of eye-related disorders and increasing global aging population is driving the age-related macular degeneration market. In addition, growing market trends such as the advancement of gene therapy for age-related macular degeneration will lead to the development of medical treatment for age-related macular degeneration. According to our research report, the Age-Related Macular Degeneration industry is valued at USD 8.62 billion in 2022.

However, only a few drugs, mainly anti-VEGF, are currently approved for the treatment of age-related macular degeneration. In addition, anti-VEGF drugs require repeated and uncomfortable intraocular injections, which increases the burden and leads to treatment non-compliance. Neither insurance nor Medicare will cover the cost of such drugs, slowing the expansion of the AMD treatment market. Market expansion may be limited even by strict FDA requirements.

Industry Trends:

Worldwide, advanced AMD is the leading cause of permanent blindness and visual impairment. As a result, the market is growing as AMD workloads grow. Also, according to the Canadian Ophthalmological Society, age-related wet macular degeneration is one of the significant causes of vision loss in adults over 65.

Anticipated launch of potential therapeutics may increase the market size in the future, aided by the growth of the commonly diagnosed age-related macular degeneration community.

Upcoming treatments such as OPT-302, KSI-301, RGX-314, AKST4290 and others have the prospects to create a significant positive change in the size of the Wet-AMD market.

Companies adopt various strategic alliances to expand in multiple regions. Investments in research have increased to develop drugs to treat AMD.

New product launches contribute to Dry AMD’s growth

On the basis of type, the age-related macular degeneration (AMD) market is segmented into; Wet AMD and Dry AMD. Dry AMD will witness the fastest growth during the forecast period due to the expected launch of promising product candidates and the disease burden of dry AMD. Dry AMD accounts for 85-90% of all cases of macular degeneration. Treatment of dry macular degeneration is currently limited to vitamin forms. However, various new therapeutic options for its treatment are already in the medical plan, such as Luminate, Zimura and Intravitreal pegcetacoplan. The approval of these potential candidates could increase the rise of the dry AMD segment in the future.

Eylea products have the highest market share

The age-related macular degeneration (AMD) market by product is categorized into Eylea, Lucentis, Beovu and others. The Eylea category dominates due to its wide market penetration and patent protection. In 2011, intravitreal injection of aflibercept was approved for Eylea by the FDA. It stops VEGF from working in wet AMD. Therefore, it treats diabetic macular edema, wet AMD and macular edema. However, the demand for Beovu, on the other hand, is expected to grow at a significant pace during the forecast period owing to its higher drying efficiency, patent protection and triumph in the treatment of severe cases of wet AMD.

Reimbursement coverage will increase the growth of specialty pharmacies

By distribution channel, the age-related macular degeneration (AMD) market is segmented into hospital pharmacies, specialty pharmacies, and online pharmacies. The specialty pharmacy segment will witness the fastest growth during the forecast period due to easy access to drugs and reimbursement coverage offered by specialty pharmacies. For example, CVS Caremark provides Eylea, Lucentis, Avastin and Beovu prescription insurance to eligible retirees and employees enrolled in the Public Employees Insurance Program (PEIP). This initiative will drive the growth of the segment.

Type – Market Breakdown from 2 Perspectives:

1. Wet AMD

2. Dry AMD

Product – Market Breakdown from 4 Perspectives:

1. Eylea

2. Lucentis

3. Beowu

4. Others

Chanel Distribution – Market Breakdown from 3 Perspectives:

1. Hospital pharmacy

2. Special pharmacy

3. Online pharmacy

Region – Breakdown of the market into 5 regions

1. North America

2. Europe

3. Asia-Pacific region

4. Latin America

5. Middle East and Africa

The company is covered by 3 points of view:

  • Review

  • A recent development

  • income

Company Analysis:

1. F. Hoffman – La Roche Ltd.

2. Bayer AG

3. Abbvie

4. GSK Plc.,

5. Novartis AG,

6. Regeneron Pharmaceuticals

7. Bausch Health Companies

8. Alimera Sciences Inc

Main topics covered:

1. Introduction

2. Research methodology

3. Summary

4. Market dynamics

5. Global Age-Related Macular Degeneration Market

6. Market Share – Global Age-Related Macular Degeneration Market

7. Type – Global Age Related Macular Degeneration Market

8. Product – Global Age-Related Macular Degeneration Market

9. Distribution Channel – Global Age-Related Macular Degeneration Market

10. Region – Global Age-Related Macular Degeneration Market

11. Key Players Analysis

For more information on this report, visit https://www.researchandmarkets.com/r/xnpdfb

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We bring you the latest data on international and regional markets, key industries, leading companies, new products and the latest trends.

Leave a Comment

Your email address will not be published. Required fields are marked *